Posted on 2/2/17
Should You Own Celgene In 2017? Part 5
In the previous articles of this series, part 1, part 2, part 3, and part 4, I have discussed in detail about the pros and cons . . .
Posted on 2/2/17
Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys
If ultra-high-risk, high-reward biotech stocks are your thing, then Celldex Therapeutics(NASDAQ: CLDX) is probably on your radar right now. This beaten-down biotech stock, after all, could . . .
Posted on 2/1/17
Pfizer (PFE) Q4 2016 Results - Earnings Call Transcript
Pfizer Inc. (NYSE:PFE)Q4 2016 Earnings CallJanuary 31, 2017 10:00 am ETExecutivesCharles E. Triano - Pfizer Inc.Ian C. Read - Pfizer Inc.Frank A. D'Amelio - Pfizer Inc.Albert . . .
Posted on 2/1/17
Merck Makes Nice With Bristol-Myers Squibb
After Bristol-Myers Squibb (NYSE:BMY) claimed Merck & Co.'s (NYSE:MRK) cancer-fighting Keytruda infringed upon patents protecting Opdivo, Merck & Co. has agreed to pay Bristol-Myers Squibb $625 . . .
Posted on 2/1/17
7 Things You Might Have Missed in Pfizer's Q4 Earnings Slip
Wall Street expected Pfizer (NYSE:PFE) to report fourth-quarter revenue of $13.63 billion and earnings of $0.50 per share. The big drugmaker met the revenue expectation but . . .
Posted on 2/1/17
Pfizer's 3 Fastest-Growing Drugs
Pfizer Inc. (NYSE:PFE) is turning an important corner. After years of declining sales due to patent expiration on its megablockbuster cholesterol drug Lipitor, the company finally . . .
Posted on 2/1/17
AmerisourceBergen's (ABC) CEO Steven Collis On Q1 2017 Results - Earnings Call Transcript
AmerisourceBergen Corporation (NYSE:ABC)Q1 2017 Results Earnings Conference CallJanuary 31, 2017, 08:30 AM ETExecutivesKeri Mattox - VP, Corporate & IRSteven Collis - Chairman, President & CEOTim Guttman . . .
Posted on 2/1/17
Johnson & Johnson's Q4 Earnings: What You Need to Know
This week, healthcare giant Johnson & Johnson (NYSE:JNJ) kicked off healthcare earnings by reporting a quarter that was mostly in line with expectations. However, a closer . . .
Posted on 2/1/17
Instant Analysis: Is Teva Pharmaceutical Industries a Buy on the Dip?
IMAGE SOURCE: THE MOTLEY FOOL.What happened?Teva Pharmaceutical Industries (NYSE:TEVA) took another stock market hit after a U.S. District Court invalidated four method of use patents protecting . . .
Posted on 2/1/17
Dayton Children’s Hospital Selects InstaMed, the First and Only P2PE v2.0 Solution for Healthcare
PHILADELPHIA & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--InstaMed, healthcare’s most trusted payments network, has been selected by Dayton Children’s, a multi-specialty pediatric hospital in Dayton, OH, as the . . .
Posted on 1/31/17
South Jersey Dental Study Club Expands its Continuing Education Programs to the Jersey Shore
South Jersey Dental Study Club (SJDSC), a membership organization providing the region's dental professionals with fully accredited continuing education, announces the expansion of SJDSC to the . . .
Posted on 1/31/17
Johnson & Johnson Plus Actelion: A Good Combination?
Johnson & Johnson's (NYSE:JNJ) acquisition of Actelion (OTCPK:ALIOY) makes a lot of sense on a number of levels. There have been some concerns about the price . . .
Posted on 1/31/17
Johnson & Johnson Acquisition Makes It Better
It looks like Johnson & Johnson (NYSE:JNJ) found something to do with all its money parked in Europe. Last week management announced it was doing a . . .
Posted on 1/31/17
3 Biotech Stocks I'd Buy Right Now
Conflicting statements from the Trump administration have made owning biotech stocks feel like a roller-coaster ride in recent weeks, but there are a few stocks I'd . . .
Posted on 1/31/17
Philmont Guidance Center Joins Holy Redeemer Health System to Expand Behavioral Health Services
Holy Redeemer Health System announced a new partnership with Philmont Guidance Center, a leading behavioral health organization with offices in Huntingdon Valley, Doylestown and Flourtown. This . . .
Posted on 1/30/17
Honeywell International's (HON) CEO Dave Cote on Q4 2016 Results - Earnings Call Transcript
Honeywell International, Inc. (NYSE:HON)Q4 2016 Earnings Conference CallJanuary 27, 2017, 09:30 AM ETExecutivesMark Macaluso - VP, IRDave Cote - Chairman & CEODarius Adamczyk - President and . . .
Posted on 1/30/17
Celgene Looks Cheap Right Now
Celgene (NASDAQ:CELG) reported fourth quarter results on Thursday morning, beating profit estimates but missing sales estimates slightly. The company remains on growth track and looks inexpensive.Celgene . . .
Posted on 1/30/17
Celgene Corporation Continues Its Double-Digit Growth
Celgene's (NASDAQ:CELG) earnings release on Thursday didn't come with many surprises since the company announced preliminary fourth-quarter results earlier this month as it usually does at . . .
Posted on 1/30/17
How Big Is the Opportunity for Celgene's Otezla Overseas?
Celgene Corp. (NASDAQ:CELG) hit a biotech home run with Otezla, a fast-growing drug that's used to treat psoriatic arthritis and psoriasis. Since winning approval for use . . .
Posted on 1/30/17
Johnson & Johnson (JNJ) Acquires Actelion (ALIOF)
The following slide deck was published by Johnson & Johnson in conjunction with this event. Tap image to enlargeREAD FULL ARTICLE HERE
Posted on 1/30/17
Celgene To Acquire Delinia For Autoimmune Technology
Quick TakePharmaceutical company Celgene (NASDAQ:CELG) has announced an agreement to acquire biotechnology company Delinia for up to $775 million in initial and contingent consideration.The deal is . . .
Posted on 1/30/17
Johnson & Johnson Sets Benchmark With Massive Actelion Price
Forget much of what you have heard about disciplined acquisitions and waiting for valuations to become realistic. Johnson & Johnson’s (NYSE:JNJ) $30bn strike for Actelion (OTCPK:ALIOF) . . .
Posted on 1/30/17
Johnson & Johnson Too Rich For You? Try This High-Yielding Pharma Stock Instead
Big pharma stocks like Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) have long been favorites of dividend growth investors and for good reason. Their recession resistant . . .
Posted on 1/30/17
3 Most Unbelievably Undervalued Biotech Stocks
Finding undervalued biotech stocks isn't as easy as it might seem. Many biotechs don't have a product on the market, so any attempt at valuation involves . . .
Posted on 1/30/17
Better Buy: Pfizer Inc. vs. Johnson & Johnson
Choosing between Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) based on past performance is an easy decision. J&J's stock performance trounced Pfizer's over the past year, . . .

